Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
Publication date: Available online 17 December 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Xueqian Li, Meng Zhou, Jiaqian Qi, Yue Han
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Leukemia | Lymphoma | Men | Myeloma | Non-Hodgkin's Lymphoma